TABLE 6.

Results of multiple linear regression analyses including the interaction term between serum UA strata and age (or gender or APOE4 or VR score) status predicting AD-CM for non-demented older subjects.

	B (95% CI)a	P
Serum UA	0.129(−0.004to0.261)	0.057
Age	0.001(−0.003to0.005)	0.563
Serum UA × Age	−0.002(−0.003to < 0.001)	0.107
Serum UA	< 0.001(−0.049to0.048)	0.988
Sex	−0.034(−0.105to0.037)	0.347
Serum UA × Sex	0.015(−0.017to0.046)	0.363
Serum UA	0.028(−0.017to0.074)	0.218
APOE4	−0.016(−0.091to0.058)	0.662
Serum UA × APOE4	−0.006(−0.040to0.028)	0.723
Serum UA	0.017(−0.006to0.041)	0.148
VRS	−0.024(−0.056to0.007)	0.131
Serum UA × VRS	0.003(−0.012to0.018)	0.700
Serum UA	0.049(0.005to0.093)	0.030
Clinical diagnosis	−0.019(−0.085to0.048)	0.581
Serum UA × Clinical diagnosis	−0.021(−0.052to0.010)	0.184

Abbreviations: UA, uric acid; AD-CM, Alzheimer’s disease signature cerebral glucose metabolism; APOE4, apolipoprotein ε4; CI, confidence interval; VRS, vascular risk score. ^aMultiple linear regression model included serum UA, age (or sex or APOE4 or VRS) and the interaction between serum UA and age (or sex or APOE4) treated as the independent variables; age, sex, education, APOE4, VRS, clinical diagnosis, were treated as covariates; and AD-CM treated as the dependent variable.